Changchun High-tech: Subsidiary GenSci143's domestic production drug registration clinical trial application approved.

Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, has received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration, allowing the clinical trial of injection GenSci143 in late-stage solid tumor patients. GenSci143 is a Class 1 biological product developed independently by Jinsai Pharmaceutical, intended for the treatment of various late-stage solid tumors such as prostate cancer and lung cancer.